Boston Scientific Corp (BSX) Balance Sheet
A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular.
Total Assets Chart for Boston Scientific Corp
Boston Scientific Corp (BSX) total assets for FY2025 were USD 43.7B, a 10.9% change from FY2024. Boston Scientific Corp's total assets grew from USD 137.4M in 1991 to USD 43.7B in 2025 (31685.3% over 34 years). Total assets compound annual growth rate: 5-year CAGR of 7.2%, 10-year CAGR of 9.2%, 20-year CAGR of 8.7%.
Total Assets (US Dollars)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- $71.45B
- Implied Share Price
- $49.30
- Enterprise Value
- $83.23B
- Revenue (TTM)
- $21.00B
- EBITDA
- $5.71B
- Profit Margin
- 17.50%
- Trailing P/E
- 19.33
- Forward P/E
- 14.93
- Price/Book (MRQ)
- 2.85
- Price/Sales (TTM)
- 3.40
- EV/EBITDA
- 14.76
- EV/Revenue
- 3.96
- Dividend Yield
- —
- Book Value
- $17.23
- Free Cash Flow (FY2025)
- $3.66B
- Free Cash Flow Yield
- 5.12%
Snapshot as of 7th August 2026 — not point-in-time controlled, may lag the live market by a few days.